Beta Bionics Inc

BBNXNASDAQ · USD
22.19USD0.00 (-2.72%)
3510

Beta Bionics Inc (BBNX) Wheel Strategy

BBNX wheel strategy scan found 3 cash-secured put setups on the previous trading day. Probability of expiring worthless is above 50%. Annualized returns reach up to 155.1%.

Read more

Running a BBNX wheel strategy lets you generate consistent premium income on Beta Bionics Inc while setting your own entry and exit prices on the underlying. Beta Bionics Inc's wheel combines cash-secured puts and covered calls into a repeatable cycle: sell puts at strikes where you'd be happy to own BBNX, and if assigned, sell calls at strikes where you'd be happy to sell. Use our scanner to find the best BBNX wheel strategy setups in real time.

The wheel works best on liquid, high-quality names with stable fundamentals and active options markets — exactly the profile many large-cap leaders fit. The mechanics are simple: sell a cash-secured put on BBNX, collect premium, and either keep the premium if it expires worthless or take assignment at a discount to current price. Once assigned, sell covered calls against the shares to keep collecting premium until they're called away. Choosing the right strikes, expirations, and IV environment is what separates a profitable BBNX wheel from a losing one.

Beta Bionics, Inc., a commercial-stage medical device company, engages in the design, development, and commercialization of solutions to enhance the health and quality of life of insulin-requiring people with diabetes. It offers iLet Bionic Pancreas, an insulin delivery device for the treatment of type 1 diabetes in adults and children six years of age and older. The company is also developing Patch Pump, an insulin pump that is designed to adhere directly to the skin and administer insulin without the need for tubing; Bihormonal iLet, which combines automated delivery of insulin and glucagon; and iLet to treat people with insulin-dependent type-2 diabetes.

It has collaboration and license agreement with Xeris Pharmaceuticals, Inc. (Xeris) to develop and commercialize a pump-compatible glucagon formulation; and development and commercialization agreement with Abbott Diabetes Care Inc. to develop and commercialize an automated insulin delivery system. The company was incorporated in 2015 and is based in Irvine, California.

The difference between a wheel that compounds and one that bleeds comes down to strike selection, IV timing, and discipline on assignment. Our scanner handles the heavy lifting: it ranks every leg of the BBNX wheel strategy by delta, premium yield, IV rank, and days to expiration, so you can deploy capital where the math works. Build your BBNX wheel strategy on data, not gut feel — and let the options wheel do what it does best: pay you to wait.

Oct 16, 202620.00$0.25$2.13-0.322557.4%155.1%0
Oct 16, 202617.50$0.30$0.78-0.182573.8%64.7%1
Jan 15, 202717.50$0.10$2.20-0.2411652.2%39.6%0

As of September 22, 2026

Run the Wheel on BBNX With Confidence

Find the best BBNX wheel strategy setups across strikes and expirations, plan ahead with at-strike values, and keep your covered calls and puts on track.

Start your 14-day free trial